Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer
Open Access
- 1 April 2003
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 88 (7) , 1017-1024
- https://doi.org/10.1038/sj.bjc.6600822
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Local recurrence after mesorectal excision for rectal cancerEuropean Journal of Surgical Oncology, 2002
- Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancerBritish Journal of Surgery, 2002
- Assessing The Predictive Value of Clinical Complete Response To Neoadjuvant Therapy for Rectal Cancer: An Analysis of 488 PatientsJournal of the American College of Surgeons, 2002
- Neoadjuvant Chemoradiation for Rectal Cancer: Analysis of Clinical Outcomes From a 13-Year Institutional ExperienceAnnals of Surgery, 2001
- Improved Survival and Reduction in Local Failure Rates After Preoperative RadiotherapyAnnals of Surgery, 1999
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998
- Rectal CancerArchives of Surgery, 1998
- Time-dependent interactions between 5-fluorouracil and mitomycin C on a human colon carcinoma cell line, HCT-8, in vitroEuropean Journal of Cancer and Clinical Oncology, 1989
- LOCAL RECURRENCE OF RECTAL ADENOCARCINOMA DUE TO INADEQUATE SURGICAL RESECTIONThe Lancet, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958